BCL2 and acute lymphoblastic leukemia: Asynchronous ALL cells treated with the Bcl-2/Bcl-xL inhibitor ABT-263, which induces rapid intrinsic apoptosis by disrupting Bcl-2/Bcl-xL suppression of prodeath Bcl-2 proteins (34), was used as a positive control.